Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies

Read full text
Authors: Pierre Rosenbaum, Cyril Planchais, Timothée Bruel, Maxime Beretta, Isabelle Staropoli, William-Henry Bolland, Florence Guivel‐Benhassine, Delphine Planas, French COVID Cohort Study Group, CORSER Study Group, Olivier Schwartz, Hugo Mouquet
Cited by: 0
References: 97

Abstract

SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD) of the spike protein can potently neutralize infection and exert additional antiviral functions. Here, we characterize the functional profiles of human RBD-specific memory B cell antibodies elicited by ancestral SARS-CoV-2 infection. While SARS-CoV-2 neutralizing antibodies, mainly class 1 and 3 anti-RBD antibodies, often lose binding and neutralizing activity against Omicron variants, most non-neutralizers that bind conserved RBD epitopes remain broadly reactive. Despite their restricted cross-reactivity, neutralizing antibodies mediate Fc-effector functions including antibody-dependent cellular cytotoxicity, phagocytosis, and complement deposition. Most neutralizers also enhance binding of antibodies that target the SARS-CoV-2 spike fusion peptide via receptor-mimetic allostery. In contrast, broadly reactive non-neutralizers fail to trigger phagocytic or allosteric effects. Thus, viral escape primarily affects neutralizing, polyfunctional antibodies, whereas cross-reactive non-neutralizing antibodies, which exert limited antiviral effects, may apply minimal immune pressure.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Protein purification and stability Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
9
Pages
117345–117345
Publication date
1 September 2026
Language
EN